Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity.
Animals
Antipsychotic Agents
/ administration & dosage
Cocaine
/ pharmacology
Disease Models, Animal
Dizocilpine Maleate
/ pharmacology
Dopamine
/ metabolism
Dose-Response Relationship, Drug
Glutamic Acid
/ metabolism
Ketamine
/ pharmacology
Locomotion
/ drug effects
Male
Mice
Oxazepines
/ administration & dosage
Piperazines
/ administration & dosage
Pyridines
/ administration & dosage
Reflex, Startle
/ drug effects
Schizophrenia
/ drug therapy
Journal
Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
6
1
2021
medline:
15
12
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
The pyridobenzoxazepine compound, 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13), has been developed as a potential antipsychotic drug. We tested the hypothesis that JL13 is efficacious in both dopaminergic and glutamatergic animal models of schizophrenia. We investigated JL13 for its efficacy to prevent cocaine- and ketamine-induced hyperlocomotion and MK-801-induced deficits in prepulse inhibition (PPI) of the startle reflex. Male Swiss mice received injections of JL13 (0.1-10 mg/kg) and were tested in the open field for basal locomotion. In separate experiments, the animals received injections of JL13 (0.1-3 mg/kg) followed by cocaine (10 mg/kg), ketamine (60 mg/kg), or MK-801 (0.5 mg/kg) and were tested in the open field for hyperlocomotion. In addition, it was also tested if JL13 prevented MK-801-induced disruption of PPI. Only the highest dose of JL13 impaired spontaneous locomotion, suggesting its favorable profile regarding motor side effects. At doses that did not impair basal motor activity, JL13 prevented cocaine-, ketamine-, and MK-801-induced hyperlocomotion. Moreover, JL13 prevented MK-801-induced disruption of PPI. Extending previous findings, this study shows that JL13 exerts antipsychotic-like activity in both dopaminergic and glutamatergic models. This compound has a favorable pharmacological profile, similar to second-generation antipsychotics.
Identifiants
pubmed: 33399294
doi: 10.1097/FBP.0000000000000595
pii: 00008877-202102000-00002
doi:
Substances chimiques
5-(4-methylpiperazin-1-yl)-8-chloropyrido(2,3-b)(1,5)benzoxazepine fumarate
0
Antipsychotic Agents
0
Oxazepines
0
Piperazines
0
Pyridines
0
Glutamic Acid
3KX376GY7L
Ketamine
690G0D6V8H
Dizocilpine Maleate
6LR8C1B66Q
Cocaine
I5Y540LHVR
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2-8Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bruhwyler J, Liégeois J-F, Chleide E, Rogister F, Damas J, Delarge J, Mercier M. (1992). Comparative study of typical neuroleptics, clozapine and newly synthesized clozapine-analogues: correlations between neurochemistry and behaviour. Behav Pharmacol. 3:567–579.
Bruhwyler J, Liégeois J-F, Bergman J, Carey G, Goudie A, Taylor A, et al. (1997). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. Pharmacol Res. 36:255–264.
Carlsson ML, Carlsson A, Nilsson M. (2004). Schizophrenia: from dopamine to glutamate and back. Curr Med Chem. 11:267–277.
Casey DE, Bruhwyler J, Delarge J, Géczy J, Liégeois J-F. (2001). The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates. Psychopharmacology (BERL). 157:228–235.
da Silveira VT, Röpke J, Matosinhos AL, Issy AC, Del Bel EA, de Oliveira AC, Moreira FA. (2018). Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity. Naunyn Schmiedebergs Arch Pharmacol. 391:761–768.
de Matos LO, de Araujo Lima Reis AL, Lopes Guerra LT, de Oliveira Guarnieri L, Moraes MA, Arabe LB, et al. (2020). Early postnatal l-Dopa treatment causes behavioral alterations in female vs. male young adult Swiss mice. Neuropharmacology. 170:108047.
Ellenbroek BA, Liégeois J-F. (2003). JL 13, an atypical antipsychotic: a preclinical review. CNS Drug Rev. 9:41–56.
Ellenbroek BA, Liégeois J-F, Bruhwyler J, Cools AR. (2001). Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J Pharmacol Exp Ther. 298:386–391.
Fejgin K, Safonov S, Pålsson E, Wass C, Engel JA, Svensson L, Klamer D. (2007). The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl). 191:377–385.
Fendt M, Koch M. (2013). Translational value of startle modulations. Cell Tissue Res. 354:287–295.
Gardner DM, Baldessarini RJ, Waraich P. (2005). Modern antipsychotic drugs: a critical overview. CMAJ. 172:1703–1711.
Gobira PH, Ropke J, Aguiar DC, Crippa JA, Moreira FA. (2013). Animal models for predicting the efficacy and side effects of antipsychotic drugs. Braz J Psychiatry. 35 (Suppl 2):S132–S139.
Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H, et al. (2017). The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry. 174:840–849.
Howes O, McCutcheon R, Stone J. (2015). Glutamate and dopamine in schizophrenia: an update for the 21 st century. J Psychopharmacol. 29:97–115.
Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. (2009). Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 15:2550–2559.
Issy AC, Salum C, Del Bel EA. (2009). Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice. Behav Brain Res. 205:475–481.
Kapur S. (2004). How antipsychotics become anti-“psychotic” – from dopamine to salience to psychosis. Trends Pharmacol Sci. 25:402–406.
Kapur S, Mamo D. (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 27:1081–1090.
Kapur S, Mizrahi R, Li M. (2005). From dopamine to salience to psychosis–linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 79:59–68.
Laruelle M. (2014). Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 14:97–102.
Leite JV, Guimaraes FS, Moreira FA. (2008). Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol. 578:222–227.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 373:31–41.
Liégeois J-F, Bruhwyler J, Hendrick JC, Delarge J, Legros JJ, Damas J. (2002). Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats. Neurosci Lett. 319:49–52.
Liégeois J-F, Deville M, Dilly S, Lamy C, Mangin F, Résimont M, Tarazi FI. (2012). New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation. J Med Chem. 55:1572–1582.
Liégeois J-F, Mouithys-Mickalad A, Bruhwyler J, Delarge J, Petit C, Kauffmann JM, Lamy M. (1997). JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena. Biochem Biophys Res Commun. 238:252–255.
Liégeois J-F, Rogister FA, Bruhwyler J, Damas J, Nguyen TP, Inarejos MO, et al. (1994). Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study. J Med Chem. 37:519–525.
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al.; CATIE Investigators. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 163:600–610.
Meltzer HY, Li Z, Kaneda Y, Ichikawa J. (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 27:1159–1172.
Meltzer HY, Stahl SM. (1976). The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 2:19–76.
Moghaddam B, Javitt D. (2012). From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 37:4–15.
Moreira FA, Guimaraes FS. (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol. 512:199–205.
Pedrazzi JF, Issy AC, Gomes FV, Guimarães FS, Del-Bel EA. (2015). Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl). 232:3057–3065.
Snyder SH. (1972). Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry. 27:169–179.
Swerdlow NR, Braff DL, Geyer MA. (2016). Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 30:1072–1081.
Tarazi FI, Moran-Gates T, Gardner MP, Graulich A, Lamy C, Liégeois J-F. (2007). Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors. J Mol Neurosci. 32:192–198.
van Os J, Kapur S. (2009). Schizophrenia. Lancet. 374:635–645.
Viana TG, Almeida-Santos AF, Aguiar DC, Moreira FA. (2013). Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice. Basic Clin Pharmacol Toxicol. 112:319–324.
Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 159:255–262.